Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability - Wikidata - awgldk - TriplyDB

Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability

Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability

http://www.wikidata.org/entity/Q26771652

about

Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis.Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis.Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?Precision Medicine: The new era in medicine.Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.Schistosoma japonicum cystatin attenuates murine collagen-induced arthritis.Proteomics to predict the response to tumour necrosis factor-α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score.Willie Sutton Was Right: It's Time to Turn to the Synovium to Drive Rheumatoid Arthritis Therapy.Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.

P2860

Q36133726-9DB9F56D-ADD8-4E50-88B5-B6A633E66D5B Q36151778-F154895A-5A00-4349-B5DB-9D0D2D4301F4 Q36255424-4E5A84CA-717C-4EDC-8AFB-A2D5C974CEF3 Q37203499-04A77370-1B29-4A91-8EEE-B031946AE0CA Q38746588-4A8E112F-1596-45C5-8845-69B541C7120F Q39364970-D778C6D6-61A1-47FF-B920-5BEA4F5DBCA7 Q39420995-BC0805CF-DD94-4800-94F4-D1D7A8B683BA Q39619842-4DDE58CA-D591-466F-A689-0C70D4DAEB59 Q40145642-3A68E907-E686-4740-A1C0-E89DC9A77E1B Q41502512-E9D1E378-F99E-4B8B-8221-85CD1C2078E0 Q53820042-CA11DE7A-8833-498A-8548-2973C823B5D5 Q55376762-19FF1A12-C868-4CAA-AA5E-6A2440E8149F

P2860

Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability

http://www.wikidata.org/entity/Q26771652

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Personalized biological treatm ...... ocus on clinical applicability

@ast

Personalized biological treatm ...... ocus on clinical applicability

@en

Personalized biological treatm ...... ocus on clinical applicability

@nl

type

label

Personalized biological treatm ...... ocus on clinical applicability

@ast

Personalized biological treatm ...... ocus on clinical applicability

@en

Personalized biological treatm ...... ocus on clinical applicability

@nl

prefLabel

Personalized biological treatm ...... ocus on clinical applicability

@ast

Personalized biological treatm ...... ocus on clinical applicability

@en

Personalized biological treatm ...... ocus on clinical applicability

@nl

P1433

Q26771652-6D4B98A4-560B-4EB4-AE46-08C10484ABEC

P1476

Q26771652-582C379C-A5E9-4075-B953-F163829CC456

P2093

Q26771652-0A29B9D2-58AB-4B82-86D2-72A1C505B577

Q26771652-A5A4E059-6EF9-4D17-B06D-15683ED54EA5

Q26771652-ABEDC7AC-571F-4EB9-8AA7-AD4810345798

Q26771652-BC0046AA-6FB7-4E39-86D8-D0D3733BFB5C

Q26771652-BF82C4FF-302B-49EE-AC5D-A3158083662F

Q26771652-C078843D-D0FB-4CA4-A17E-D682BF855A3B

Q26771652-C8C77DE4-4C22-4194-8FEF-4ED043358D08

Q26771652-D844D5FD-69DE-4799-8357-1A13A0894024

P2860

Q26771652-0069DF92-0A3D-47CE-A936-B86D1510070C

Q26771652-0C624332-F2AF-4618-BCC7-7C9D7F3F7BBB

Q26771652-10E4D3DE-6FA7-43E9-88E7-2E54A0ECD96B

Q26771652-2220F1EB-5A2D-467E-888F-62EB3005E9AE

Q26771652-232816CD-FC5F-4033-9960-90222D08EA8E

Q26771652-23D6F58C-AEEA-4400-99B2-5D40B5876039

Q26771652-27D25B62-2900-43F5-9D3C-8DBD0C020E5D

Q26771652-312DCEB1-6CD4-4DFF-BE1A-1E6CFE589221

Q26771652-32E71A29-330C-4DE7-950C-F14BF55914D4

Q26771652-3549787D-7974-4210-9FA4-F656CABC6DFC

P304

Q26771652-54E59DA8-DF61-44C1-9A04-2C1A3E871DA7

P31

Q26771652-85BEA931-BE91-4384-87DF-0607B874F191

Q26771652-D8DA9E2C-8947-413F-A3B1-B252814092D8

P3181

Q26771652-EFB2162F-8D9C-4A73-AB7A-DFE3177D1B43

P356

Q26771652-CCBBAC34-B7AA-4207-81E7-634C5DA67454

P407

Q26771652-E30FA4D3-FCD9-4A65-BA72-0713C213484D

P433

Q26771652-7761CA86-FBD4-4487-B2B0-941A5B251F4D

P478

Q26771652-D4DEA428-C136-426B-A2B8-7D3885B52E85

P577

Q26771652-7E8709FD-07D9-4F46-BC62-CDEFDD9A706B

P698

Q26771652-4144FEB5-F5D5-445A-8E9F-D5E30D571C2C

P3181

P356

P1433

P1476

Personalized biological treatm ...... ocus on clinical applicability

@en

P2093

Anne C A Marijnissen

http://www.w3.org/2001/XMLSchema#string

Bart V J Cuppen

http://www.w3.org/2001/XMLSchema#string

Floris P J G Lafeber

http://www.w3.org/2001/XMLSchema#string

Jacob M van Laar

http://www.w3.org/2001/XMLSchema#string

Jan J Sprengers

http://www.w3.org/2001/XMLSchema#string

Johannes W J Bijlsma

http://www.w3.org/2001/XMLSchema#string

Paco M J Welsing

http://www.w3.org/2001/XMLSchema#string

Sandhya C Nair

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.

Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response.

An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis.

Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients.

P304

826-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

3513354

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/RHEUMATOLOGY/KEV421

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26715775

http://www.w3.org/2001/XMLSchema#string